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Relapse of hematological malignancies after hematopoietic stem cell transplantation (HCT) is associated with
poor prognosis. A second HCT represents one of the few therapeutic options for these high-risk patients. For
children undergoing second HCT, the outcome data are particularly limited. We, therefore, conducted a retro-
spective single-institution study and report the outcomes and prognostic variables associated with overall
survival (OS) and relapse in 43 pediatric patients who underwent a secondHCT between 2000 and 2013. Eleven
of the 43 patients who underwent transplantation remain alive and disease-free at a median follow-up of 49
months (range, 5 to 127 months). The 5-year probability of OS for the entire cohort was 24%. Patients who had
early relapse (<6months) after ﬁrst HCT had signiﬁcantly worse OS than those who relapsed late (>6months),
with 5-year OS at 11% versus 34%, respectively (hazard ratio [HR], 2.24; 95% conﬁdence interval [CI],1.21 to 4.93;
P¼ .013). Active disease at time of second HCT was also associated with a signiﬁcantly increased risk of relapse
(subdistributionhazard ratio [SHR], 2.36; P¼ .049) for the entire cohort and relapsewas themost frequent cause
of death (23 of 32; 72%). On subgroup analysis for the 34patientswith leukemia alone, presence of active disease
was associated both with a signiﬁcant decrease in OS (SHR, 2.28; 95% CI, 1.02 to 5.09; P ¼ .044) and signiﬁcant
increase in the rate of relapse (SHR, 2.46; P¼ .046). By contrast, underlying disease, donor source, conditioning
regimen, or development of GVHD did not modify OS or rate of relapse. Hence, a second HCT appears to be a
useful therapeutic option in children with relapsed hematological malignancies that is most likely to beneﬁt
those individuals with late onset of relapse and with low disease burden at the time of transplantation.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Although hematopoietic stem cell transplantation (HCT)
can cure hematological malignancy, the relapse rate after
treatment can be as high as 70% [1-3]. The treatment of
patients who relapse after HCT is challenging and of variable
success. These patients may be treated by withdrawal of
immune suppression to harness a graft-versus-leukemia
effect, infusion of donor lymphocytes, or by further chemo-
therapy with or without a second HCT [3-5]. The choice of
treatment depends upon underlying clinical factors, such asedgments on page 1271.
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ty for Blood and Marrow Transplantation.primary diagnosis, disease status, organ function, and
presence of graft-versus-host disease (GVHD) and other
associated comorbidities.
For select patients, a second HCT may be curative. The
overall survival (OS) forpatientswhoundergo secondHCTshas
been reported to be as low as 0% and as high as 67% [6,7]. For
adults undergoing a second HCT, several prognostic factors
correlate with survival, including remission status at second
HCT and duration between ﬁrst transplantation and relapse
[1,2,7]. For children, however, prognostic data are limited
[8-10]. We, therefore, conducted a retrospective single-
institution study to determine the outcome for pediatric pa-
tients who received a second HCT for relapsed hematological
malignancies to identify prognostic factors and the patients
who are most likely to beneﬁt from this intervention.
Table 1
Disease and Transplantation Characteristics
Characteristic First HSCT Second HSCT
Age at transplantation, median (range), yr 7 (1-18) 8 (2-20)
Diagnosis
ALL 14 (32.6) 13 (30.2)
AML 19 (44.2) 21 (48.8)
MDS 7 (16.3) 6 (14.0)
JMML 1 (2.3) 1 (2.3)
CML 1 (2.3) 1 (2.3)
Hodgkin’s 1 (2.3) 1 (2.3)
Disease status at HSCT
CR1 11 (25.6) 0 (0)
CR2 12 (27.9) 12 (27.9)
CR3 0 (0) 7 (16.3)
Relapse 1 6 (14.0) 12 (27.9)
Relapse 2 0 (0) 11 (25.6)
Relapse 3 0 (0) 0 (0)
Primary refractory disease 7 (16.3) 0 (0)
MDS 7 (16.3) 1 (2.3)
Site of relapse
BM 34 (79) 33 (76.7)
Extramedullary 3 (6.9) 4 (9.3)
BM/extramedullary 6 (13.9) 6 (13.9)
Conditioning
MAC 37 (86.0) 13 (30)
RIC 6 (14.0) 28 (65.1)
None 0 (0) 2 (4.6)
TBI
TBI 31 (79.5) 18 (41.9)
No TBI 12 (27.9) 25 (58.1)
GVHD prophylaxis
CNI/MTX 25 (58.1) 8 (18.6)
CD34 selection 9 (20.9) 21 (48.8)
Tacrolimus alone 4 (9.3) 8 (18.6)
Other 3 (7.0) 2 (4.7)
None 2 (4.7) 4 (9)
Donor type
Auto 2 (4.6) 0 (0)
MSD 10 (23.2) 1 (2.3)
MMRD 4 (9.3) 3 (6.9)
MUD 12 (27.9) 13 (30.2)
MMUD 8 (18.6) 5 (11.6)
Haplo-identical 7 (16.3) 21 (48.8)
Stem cell source
BM 28 (65.1) 18 (41.9)
PBSCT 12 (27.9) 25 (58.1)
Cord 3 (6.9) 0 (0)
JMML indicates juvenile myelomonocytic leukemia; CML, chronic myeloid
leukemia; CR, complete remission; BM, bone marrow; TBI, total body irra-
diation; CNI/MTX, calcineurin inhibitor/methotrexate; MSD, matched sib-
ling donor; MMRD, mismatched related donor; MUD, matched unrelated
donor; MMUD, mismatched unrelated donor; PBSCT, peripheral blood stem
cell transplantation.
Data presented are n (%), unless otherwise indicated.
Table 2
Outcomes after Second HSCT
Outcome Value
Days to engraftment, median (range) 16 (8-22)
Acute GVHD
Grade II to III 6 (75%)
Grade IV 2 (25%)
Chronic GVHD
Limited, n (%) 5 (100%)
Extensive, n (%) 0 (0%)
Five-year cumulative incidence of relapse 55%
Median time to relapse, (range), d 95 (13-755)
Five-year cumulative incidence of NRM 20%
Median time to NRM, (range), d 188 (5-1938)
Five-year DFS 25%
Five-year OS
Entire cohort 24%
Early relapse (<6 mo) 11%
Late relapse (>6 mo) 34%
Subgroup with leukemia with active disease 12%
Subgroup with leukemia in remission 35%
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Study Design and Inclusion Criteria
This study was a retrospective chart review, which was approved by the
institutional review board. Between January 1, 2000 and August 30, 2013, 43
patients underwent a second HCT for relapse and all were included in this
analysis.Deﬁnitions
The following data were collected: engraftment status, acute and
chronic GVHD, transplantation-related mortality, relapse, disease-free sur-
vival (DFS), and OS. Engraftment was deﬁned as an absolute neutrophil
count> 500/mL for 3 consecutive days in those surviving at least 28 days
after second HCT. GVHD was deﬁned using standard published criteria [11].
Relapse was deﬁned by morphological or cytogenetic evidence of disease at
any site. Active disease was deﬁned as morphologic or cytogenetic evidence
of disease at any site at time of transplantation. Nonrelapse mortality (NRM)
was deﬁned as death occurring while in continuous remission. DFS was
deﬁned as survival without evidence of recurrent disease. OS was evaluated
as the outcome from second HCT to last follow-up or death.Statistical Analysis
Descriptive statistics were calculated to summarize disease and trans-
plantation characteristics. We analyzed OS and DFS using the Kaplan-Meier
method and made comparisons between groups using the log-rank test. We
used univariate Cox regression analysis to identify factors signiﬁcantly
associated with OS and DFS. Cumulative incidences were estimated for
engraftment, relapse, and NRM, with death or relapse as a competing risk.
We used univariate competing risk regression analysis to assess the impact
of transplantation variables on relapse and NRM [12].
RESULTS
Patient and Disease Characteristics
Forty-three patients made up the study cohort, of whom
26 were male. The median age was 7 years (range, 1 to 18) at
ﬁrst HCT and 8 years (range, 2 to 20) at second HCT. Acute
myeloid leukemia (AML) was the most common diagnosis at
both the ﬁrst (19 of 43) and second HCT (21 of 43). There
were 21 patients with AML at time of second HCT compared
with 19 at ﬁrst HCT as 2 patients (1 with myelodysplastic
syndrome [MDS] at ﬁrst HCT and 1 with acute lymphoblastic
leukemia [ALL] at ﬁrst HCT) developed secondary AML. More
than one half of the patients (24 of 43, 56%) had evidence of
active disease going into their second HCT. The majority of
patients received a second HCT for bonemarrow relapses (33
of 43). Disease characteristics are summarized in Table 1.
Transplantation Procedures
Transplantation characteristics for ﬁrst and second HCTs
are summarized in Table 1. The median time between the
ﬁrst and second HCTs was 14months (range, 5 to 57months).
Two patients had undergone an autologous HCT as the ﬁrst
HCT, 1 patient with Hodgkin’s lymphoma and the other with
acute promyelocytic leukemia, but all patients received an
allogeneic HCT for their second HCT. Donor types, stem cell
sources, and conditioning regimens used at ﬁrst and second
HCT are summarized in Table 1. The choice of donor and
conditioning regimen at second HCT was dependent upon
donor availability and clinical status of the patient. For 33 of
the 43 patients, a different donor was identiﬁed for the
second HCT. The 2 patients who did not receive any condi-
tioning at the second HCT underwent transplantation with
the same donor.
Engraftment
Two patients died before engraftment. Of the 41 evalu-
able patients, 39 patients engrafted (95%). The median time
to engraftment was 16 days (Table 2). The 2 patients who did
S. Naik et al. / Biol Blood Marrow Transplant 21 (2015) 1266e12721268not engraft received third HCTs for graft failure; 1 from the
same donor and 1 from a different donor. One patient re-
mains disease free; the other patient died of relapsed
disease.GVHD
The incidence of grade II to IV acute GVHDwas low at 6 of
43 patients (14%) after the ﬁrst HCTand 8 of 43 patients (19%)
after the second HCT. The incidence of limited chronic GVHD
was also lowat 4 of 43 patients (9%) after ﬁrst HCTand 5 of 43
patients (12%) after second HCT. No patient had extensive
chronic GVHD after the ﬁrst or second HCT. There was no
correlation between occurrence of GVHD at ﬁrst or second
HCT and the type of donor or conditioning regimen used.Figure 2. Time to relapse after ﬁrst HCT predicts outcome. Improved OS in
patients who relapse > 6 months after ﬁrst HCT compared with those who
relapse < 6 months after ﬁrst HCT (HR, 2.44; 95% CI, 1.21 to 4.93; P ¼ .013).Survival Analysis and Contributing Factors
Eleven of the 43 patients who underwent transplantation
remain alive and disease free at a median follow-up of 49
months (range, 5 to 127 months). The probabilities of OS at
100 days, 1 year, 5 years, and 10 years are 86%, 48%, 24%, and
20%, respectively (Figure 1). The probabilities of DFS at 100
days, 1 year, 5 years, and 10 years are 65%, 31%, 25%, and 21%,
respectively.
To analyze risk factors, we ﬁrst stratiﬁed patients ac-
cording to time to relapse after ﬁrst HCT. Eighteen patients
relapsed 6 months (early) and 25 patients relapsed >6
months (late) after the ﬁrst HCT. Patients who had early
relapse had signiﬁcantly worse OS than those who relapsed
late after the ﬁrst HCT (OS for early versus late at 1 year was
22% versus 66% and at 5 years was 11% versus 34%, respec-
tively; hazard ratio (HR), 2.24; 95% conﬁdence interval (CI),
1.21 to 4.93; P ¼ .013) (Figure 2).
We stratiﬁed the entire cohort by disease status, and in
patients who had active disease at time of second HCT, we
observed no increased risk of NRM compared with those
receiving a transplant in remission (subdistribution hazard
ratio [SHR], .89; P ¼ .86). There was a trend toward worse OS
in patients treated in relapse but this, too, did not reach
statistical signiﬁcance (HR,1.85; 95% CI, .89 to 3.86; P¼ .099).Figure 1. Overall survival after second HCT. Kaplan-Meier curve showing OS. The pro
20%, respectively.By contrast, active disease at time of second transplantation
was associated with a signiﬁcantly increased risk of relapse
(SHR, 2.36; P¼ .049). Of the 24 patients with active disease at
second HCT, just 3 (13%) survived, whereas for the 19 pa-
tients in remission, 8 patients (42%) survived. Of the 3 sur-
vivors with active disease, 1 patient had Hodgkin’s disease
with persistent adenopathy at time of second HCT and had
undergone an autologous transplantation at ﬁrst HCT. The
second patient with pre-B cell ALL had cytogenetic evidence
of disease by ﬂuorescein in situ hybridization at time of
transplantation but no blasts in the bone marrow. The third
patient had MDSerefractory anemia with excess blasts
without progression to acute leukemia. Of note, all 3 patients
had relapsed >6 months after ﬁrst HCT. No patient
with active disease who relapsed early has been a survivor
(0 of 11).
As our patient population included patients with MDS
and Hodgkin’s lymphoma, a subgroup analysis was
performed for the 34 patients with leukemia alone. This
subgroup analysis, unlike analysis of the entire cohort, now
revealed the active-disease group to have a statistically
signiﬁcant decrease in OS (HR, 2.28; 95% CI, 1.02 to 5.09;babilities of OS at 100 days, 1 year, 5 years, and 10 years are 86%, 48%, 24%, and
Figure 3. Disease status at time of second HCT predicts outcome for patients
with acute leukemia. Improved OS in patients with acute leukemia who are in
remission at time of second HCT compared with those with active disease (HR,
2.28; 95% CI, 1.02 to 5.09; P ¼ .044).
Table 3
Univariate Analysis of Factors Inﬂuencing OS, Relapse, and NRM
Variable OS: Cox Relapse: CRR NRM: CRR
HR P Value SHR* P Value SHR* P Value
Donor source
Alternate 1.00 .842 1.00 .570 1.00 .310
Haplo 1.07 1.26 .49
Conditioning
MAC 1.00 .676 1.00 .990 1.00 .320
RIC 1.41 1.01 3.45
No conditioning 1.60 .88 8.13
Diagnosis
ALL 1.20 .967 2.37 .660 .21 .610
AML 1.32 1.73 .70
Other 1.20 1.14 1.09
MDS 1.00 1.00 1.00
Disease status at transplantationeall patients
Active disease 1.85 .099 2.36 .049 .89 .860
Remission 1.00 1.00 1.00
Disease status at transplantationesubgroupy
Active disease 2.28 .044 2.46 .046 .91 .900
Remission 1.00 1.00 1.00
Time to relapse at ﬁrst transplantation
6 mo 2.44 .013 1.24 .600 3.16 .096
>6 mo 1.00 1.00 1.00
TBI at second transplantation
No 1.43 .333 1.43 .380 1.46 .590
Yes 1.00 1.00 1.00
Grade II-IV GVHD after ﬁrst transplantation
No .72 .539 1.01 .980 1.30 .810
Yes 1.00 1.00 1.00
Grade II-IV GVHD after second transplantation
No 2.10 .131 1.83 .310 .87 .850
Yes 1.00 1.00 1.00
Haplo indicates haploidentical donor.
* Fine-Gray: subdistribution hazard ratio.
y Subgroup: Patients with acute leukemia (ALL and AML).
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relapse (SHR, 2.46, P ¼ .046) compared with patients who
underwent transplantation in remission (Figure 3).
Underlying disease diagnosis was not signiﬁcantly asso-
ciated with overall survival (5-year OS: ALL, 17%; AML, 26%;
MDS, 25%; and others, 33%; P ¼ .967). Likewise, OS was
similar whether a haploidentical or alternate donor was used
(5-year OS: haploidentical, 23.6%; alternate, 23.8%; P ¼ .842)
Furthermore, survival was not inﬂuenced by the type of
conditioning (myeloablative conditioning [MAC] or reduced-
intensity conditioning [RIC]) used (5-year OS: MAC, 33.8%;
RIC 20.8%; P ¼ .408).
Mortality
Of the 43 patients receiving a second HCT, 32 patients
died. The most frequent cause of death (23 of 32; 72%) was
relapse. The cumulative incidence of relapse was 28% at day
100 and 53% and 55% at 1 year and 5 years, respectively. The
median time to relapse after second transplantation was 95
days (range, 13 to 755), with all relapses occurring within 2.1
years. Nine of these 32 deceased patients died from NRM.
The cumulative incidence of NRMwas 7% at day 100 and 17%
and 20% at 1 year and 5 years, respectively. The cause of NRM
was infection (n ¼ 4), organ failure (n ¼ 3), diffuse alveolar
hemorrhage (n ¼ 1), and recurrent neuroblastoma in a pa-
tient who received both allogeneic HCTs for therapy-related
MDS (n ¼ 1).
Third Transplantations for Relapsed Malignancies
Eight patients underwent a third HCT for relapsed ma-
lignancy after a second HCT. All 8 patients had active disease
at the time of the third HCT. The median time between the
second and third HCT was 58 days. No patient survived a
third HCT for relapsed malignancy. In addition, 2 patients
received third HCTs for graft failure; 1 patient remains dis-
ease free and the other patient died of relapsed disease.
DISCUSSION
For patients with hematological malignancies who
relapse after a HCT, few curative options exist and prognosis
remains poor. A second HCT may be an option for some pa-
tients and the 2009 American Society of Hematology
evidence-based guidelines provide a strong recommenda-
tion (1B) for a second HCT for patients with relapse after ﬁrst
HCT, as select patients can beneﬁt and remain alive anddisease free [7]. It is imperative to identify patients who are
most likely to beneﬁt from a second HCT and to identify
patients for whom a second HCT might be futile.
In our cohort of 43 pediatric patients with relapsed
hematological malignancies, we found that 25% attained
long-term DFS after a second HCT. This is comparable to
other reports that include both adults and children [13-18].
The main limitation of our study is its retrospective nature
and the small cohort of patients evaluated. We acknowledge
that this limits the validity of our conclusions.
There are few reports analyzing outcomes after second
HCTs for relapsed malignancies exclusively in pediatric pa-
tients [8-10]. To our knowledge, this is the largest pediatric
cohort reported on thus far. Previously published pediatric
reports describe outcomes in a smaller number of patients
(n¼ 24 to 27) but report a higher OS ranging between 32% to
48%. However, there are differences in patient characteristics
that could explain the differing outcomes. In these earlier
studies, most or all patients were in remission at time of
second HCT [8,10] in contrast to just 44% of our patients.
Moreover, the majority of patients in these earlier series
received transplants from matched related donors at the
second HCT [9,10], but only 1 of 43 patients in our cohort
underwent transplantation with a matched sibling donor,
whereas the remainder received transplants from either
alternate (21 of 43) or haploidentical donors (21 of 43) at the
second HCT. Indeed, in 1 report [9], nearly one half of the
patients (11 of 25) received autologous grafts at the ﬁrst HCT,
compared with only 2 of 43 of the patients reported here.
Finally, in these studies, most or all patients received MAC at
the second transplantation [8,9], whereas in our study, more
than one half (28 of 43; 65%) received RIC regimens for their
Figure 4. Indications for second HCT in pediatric patients. (A) Outcome by risk group. (B) Algorithm for considering second HCT in pediatric patients with relapsed
malignancies after ﬁrst HCT. For detail see text.
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words, our cohort likely represents a higher risk group and
probably includes more patients who might not have been
eligible to receive HCT at several other centers.
In our analysis, we found that the most important prog-
nostic factor associatedwith OSwas time to relapse after ﬁrst
HCT. We used a cut-off point of 6 months to deﬁne early
versus late relapse and found that time to relapse of <6
months was associated with statistically signiﬁcant worseOS. There were only 2 patients who relapsed early (<6
months) and survived after a second HCT that they received
within 6 months of the ﬁrst HCT. Importantly, both patients
with early relapse were in remission at time of second HCT.
Others have made similar observations in the adult setting,
albeit with different cut-off points [1,2,10,18,19]. Although
the Center for International Blood and Marrow Transplant
Research reported similar ﬁndings of higher relapse rates
and mortality using a cut-off point of 6 months [2], other
S. Naik et al. / Biol Blood Marrow Transplant 21 (2015) 1266e1272 1271groups stratiﬁed early relapse using a 1-year time point
[10,18,19].
As reported by other groups, active disease status at time
of second HCT was associated with worse outcomes in our
cohort. Previous reports evaluated outcomes only in patients
with relapsed leukemias [1,2,8]. Although there was only a
trend noted for improved survival for the entire cohort, on
subgroup analysis for patients with leukemia alone, there
was a statistically signiﬁcant improvement in survival for
patients coming to second transplantation in remission.
Hence, favorable pretransplantation disease status may be
considered as a requirement before patients with leukemia
are considered for a second HCT. The use of minimal residual
disease can deﬁne the risk of relapse before ﬁrst HCT [20,21]
and such testing before second HCT may be of equivalent
value.
A number of potential prognostic indicators were found
to have no predictive power in our study. Unlike previous
reports [1,16], we found no survival advantage after second
transplantation for patients with myeloid as opposed to
lymphoid disease. Moreover, OS and rate of relapse were
comparable across donor types and were not inﬂuenced by
use of the same or a different donor for the second HCT.
Whether MAC or RIC regimens were used at the time of
second HCT also lacked an effect on outcome. There are re-
ports of improved survival in patients who received total
body irradiation at second HCT [1,18], but we did not observe
any beneﬁt.
The effects of acute GVHD on survival after second HCT
are unclear. Some reports describe improved survival and
decreased relapse among patients with acute GVHD [1],
whereas others suggest that absence of GVHD correlated
with improved OS and DFS [18]. For patients with chronic
GVHD after second transplantations, reports show improved
OS and DFS [18,22]. The incidence of both acute and chronic
GVHD was much lower in our cohort than in other reported
studies and an effect of GVHD on outcome could not be
ascertained. These data are summarized in Table 3.
In our study, relapse was the leading cause of mortality
(23 of 43 versus 9 of 43 dying from NRM). The 5-year cu-
mulative incidence of relapse was 55% and of NRM was 20%.
In previous reports, the 3 to 5 year cumulative incidences of
relapse and NRM have ranged from 36% to 59% and 26% to
46%, respectively [1,2,18]. The lower NRM after second HCT in
our study may relate to improvements in transplantation
procedures and supportive care measures. Despite this
reduction in NRM, the OS and DFS for patients with relapsed
malignancies after an allogeneic transplantation have not
changed signiﬁcantly over the last decade [1,2,4,9,19,22-26].
This might reﬂect the fact that with improvements in upfront
nontransplantation therapies for leukemia, only those pa-
tients withmore aggressive and refractory diseases are being
referred for HCT, so that relapse after transplantation re-
mains the major challenge. None of the 8 patients who un-
derwent a third HCT for relapsed disease after a second HCT
are alive. Therefore, although we observed that third HCTs
for relapsed hematological malignancies were not of beneﬁt,
the small patient number is insufﬁcient to draw deﬁnite
conclusions.
We show that a second allogeneic HCT can be a thera-
peutic option in children with relapsed hematological ma-
lignancies, and is most likely to beneﬁt those individuals
with low disease burden at the time of transplantation and
late onset of relapse. Every attempt should, therefore, be
made to induce remission in patients with early relapse afterﬁrst HCT, before consideration for a second HCT (Figure 4).
Recently, CD19-directed chimeric antigen recep-
toreexpressing T cells have been shown to be strikingly
successful in producing complete remission in a high pro-
portion of patients with relapsed B cell ALL, including those
who have relapsed after transplantation [27]. If this or
related therapy becomeswidely available, our results suggest
that a second HCT may well become both feasible and suc-
cessful for a higher proportion of patients in need.
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